Embedded Files
Gastrointestinal Stromal Tumor (GIST) Publications:
Gastrointestinal Stromal Tumor (GIST) Publications:
Hemming ML, Benson MR, Loycano MA, Anderson JA, Andersen JL, Taddei ML, Krivtsov AV, Aubrey BJ, Cutler JA, Hatton C, Sicinska E, Armstrong SA. MOZ and Menin-MLL Complexes Are Complementary Regulators of Chromatin Association and Transcriptional Output in Gastrointestinal Stromal Tumor. Cancer Discov. 2022 Jul 6;12(7):1804-1823. doi: 10.1158/2159-8290.CD-21-0646. PubMed PMID: 35499757; PubMed Central PMCID: PMC9453853.
Hemming ML, Benson MR, Loycano MA, Anderson JA, Andersen JL, Taddei ML, Krivtsov AV, Aubrey BJ, Cutler JA, Hatton C, Sicinska E, Armstrong SA. MOZ and Menin-MLL Complexes Are Complementary Regulators of Chromatin Association and Transcriptional Output in Gastrointestinal Stromal Tumor. Cancer Discov. 2022 Jul 6;12(7):1804-1823. doi: 10.1158/2159-8290.CD-21-0646. PubMed PMID: 35499757; PubMed Central PMCID: PMC9453853.
Cousin S, Blay JY, Garcia IB, de Bono JS, Le Tourneau C, Moreno V, Trigo J, Hann CL, Azad AA, Im SA, Cassier PA, French CA, Italiano A, Keedy VL, Plummer R, Sablin MP, Hemming ML, Ferron-Brady G, Wyce A, Khaled A, Datta A, Foley SW, McCabe MT, Wu Y, Horner T, Kremer BE, Dhar A, O'Dwyer PJ, Shapiro GI, Piha-Paul SA. Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein in testis carcinoma and other cancers: Results of a Phase I/II open-label, dose escalation study. Int J Cancer. 2022 Mar 15;150(6):993-1006. doi: 10.1002/ijc.33861. Epub 2021 Nov 26. PubMed PMID: 34724226.
Cousin S, Blay JY, Garcia IB, de Bono JS, Le Tourneau C, Moreno V, Trigo J, Hann CL, Azad AA, Im SA, Cassier PA, French CA, Italiano A, Keedy VL, Plummer R, Sablin MP, Hemming ML, Ferron-Brady G, Wyce A, Khaled A, Datta A, Foley SW, McCabe MT, Wu Y, Horner T, Kremer BE, Dhar A, O'Dwyer PJ, Shapiro GI, Piha-Paul SA. Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein in testis carcinoma and other cancers: Results of a Phase I/II open-label, dose escalation study. Int J Cancer. 2022 Mar 15;150(6):993-1006. doi: 10.1002/ijc.33861. Epub 2021 Nov 26. PubMed PMID: 34724226.
Iida K, Abdelhamid Ahmed AH, Nagatsuma AK, Shibutani T, Yasuda S, Kitamura M, Hattori C, Abe M, Hasegawa J, Iguchi T, Karibe T, Nakada T, Inaki K, Kamei R, Abe Y, Nomura T, Andersen JL, Santagata S, Hemming ML, George S, Doi T, Ochiai A, Demetri GD, Agatsuma T. Identification and Therapeutic Targeting of GPR20, Selectively Expressed in Gastrointestinal Stromal Tumors, with DS-6157a, a First-in-Class Antibody-Drug Conjugate. Cancer Discov. 2021 Jun;11(6):1508-1523. doi: 10.1158/2159-8290.CD-20-1434. Epub 2021 Feb 12. PubMed PMID: 33579785.
Iida K, Abdelhamid Ahmed AH, Nagatsuma AK, Shibutani T, Yasuda S, Kitamura M, Hattori C, Abe M, Hasegawa J, Iguchi T, Karibe T, Nakada T, Inaki K, Kamei R, Abe Y, Nomura T, Andersen JL, Santagata S, Hemming ML, George S, Doi T, Ochiai A, Demetri GD, Agatsuma T. Identification and Therapeutic Targeting of GPR20, Selectively Expressed in Gastrointestinal Stromal Tumors, with DS-6157a, a First-in-Class Antibody-Drug Conjugate. Cancer Discov. 2021 Jun;11(6):1508-1523. doi: 10.1158/2159-8290.CD-20-1434. Epub 2021 Feb 12. PubMed PMID: 33579785.
Hemming ML, Coy S, Lin JR, Andersen JL, Przybyl J, Mazzola E, Abdelhamid Ahmed AH, van de Rijn M, Sorger PK, Armstrong SA, Demetri GD, Santagata S. HAND1 and BARX1 Act as Transcriptional and Anatomic Determinants of Malignancy in Gastrointestinal Stromal Tumor. Clin Cancer Res. 2021 Mar 15;27(6):1706-1719. doi: 10.1158/1078-0432.CCR-20-3538. Epub 2021 Jan 15. PubMed PMID: 33451979; PubMed Central PMCID: PMC7956056.
Hemming ML, Coy S, Lin JR, Andersen JL, Przybyl J, Mazzola E, Abdelhamid Ahmed AH, van de Rijn M, Sorger PK, Armstrong SA, Demetri GD, Santagata S. HAND1 and BARX1 Act as Transcriptional and Anatomic Determinants of Malignancy in Gastrointestinal Stromal Tumor. Clin Cancer Res. 2021 Mar 15;27(6):1706-1719. doi: 10.1158/1078-0432.CCR-20-3538. Epub 2021 Jan 15. PubMed PMID: 33451979; PubMed Central PMCID: PMC7956056.
Flavahan WA, Drier Y, Johnstone SE, Hemming ML, Tarjan DR, Hegazi E, Shareef SJ, Javed NM, Raut CP, Eschle BK, Gokhale PC, Hornick JL, Sicinska ET, Demetri GD, Bernstein BE. Altered chromosomal topology drives oncogenic programs in SDH-deficient GISTs. Nature. 2019 Nov;575(7781):229-233. doi: 10.1038/s41586-019-1668-3. Epub 2019 Oct 16. PubMed PMID: 31666694; PubMed Central PMCID: PMC6913936.
Flavahan WA, Drier Y, Johnstone SE, Hemming ML, Tarjan DR, Hegazi E, Shareef SJ, Javed NM, Raut CP, Eschle BK, Gokhale PC, Hornick JL, Sicinska ET, Demetri GD, Bernstein BE. Altered chromosomal topology drives oncogenic programs in SDH-deficient GISTs. Nature. 2019 Nov;575(7781):229-233. doi: 10.1038/s41586-019-1668-3. Epub 2019 Oct 16. PubMed PMID: 31666694; PubMed Central PMCID: PMC6913936.
Hemming ML, Lawlor MA, Andersen JL, Hagan T, Chipashvili O, Scott TG, Raut CP, Sicinska E, Armstrong SA, Demetri GD, Bradner JE. Enhancer Domains in Gastrointestinal Stromal Tumor Regulate KIT Expression and Are Targetable by BET Bromodomain Inhibition. Cancer Res. 2019 Mar 1;79(5):994-1009. doi: 10.1158/0008-5472.CAN-18-1888. Epub 2019 Jan 10. PubMed PMID: 30630822; PubMed Central PMCID: PMC6397693.
Hemming ML, Lawlor MA, Andersen JL, Hagan T, Chipashvili O, Scott TG, Raut CP, Sicinska E, Armstrong SA, Demetri GD, Bradner JE. Enhancer Domains in Gastrointestinal Stromal Tumor Regulate KIT Expression and Are Targetable by BET Bromodomain Inhibition. Cancer Res. 2019 Mar 1;79(5):994-1009. doi: 10.1158/0008-5472.CAN-18-1888. Epub 2019 Jan 10. PubMed PMID: 30630822; PubMed Central PMCID: PMC6397693.
Hemming ML, Heinrich MC, Bauer S, George S. Translational insights into gastrointestinal stromal tumor and current clinical advances. Ann Oncol. 2018 Oct 1;29(10):2037-2045. doi: 10.1093/annonc/mdy309. Review. PubMed PMID: 30101284.
Hemming ML, Heinrich MC, Bauer S, George S. Translational insights into gastrointestinal stromal tumor and current clinical advances. Ann Oncol. 2018 Oct 1;29(10):2037-2045. doi: 10.1093/annonc/mdy309. Review. PubMed PMID: 30101284.
Hemming ML, Lawlor MA, Zeid R, Lesluyes T, Fletcher JA, Raut CP, Sicinska ET, Chibon F, Armstrong SA, Demetri GD, Bradner JE. Gastrointestinal stromal tumor enhancers support a transcription factor network predictive of clinical outcome. Proc Natl Acad Sci U S A. 2018 Jun 19;115(25):E5746-E5755. doi: 10.1073/pnas.1802079115. Epub 2018 Jun 4. PubMed PMID: 29866822; PubMed Central PMCID: PMC6016782.
Hemming ML, Lawlor MA, Zeid R, Lesluyes T, Fletcher JA, Raut CP, Sicinska ET, Chibon F, Armstrong SA, Demetri GD, Bradner JE. Gastrointestinal stromal tumor enhancers support a transcription factor network predictive of clinical outcome. Proc Natl Acad Sci U S A. 2018 Jun 19;115(25):E5746-E5755. doi: 10.1073/pnas.1802079115. Epub 2018 Jun 4. PubMed PMID: 29866822; PubMed Central PMCID: PMC6016782.
Leiomyosarcoma Publications:
Hemming ML, Bhola P, Loycano MA, Anderson JA, Taddei ML, Doyle LA, Lavrova E, Andersen JL, Klega KS, Benson MR, Crompton BD, Raut CP, George S, Letai A, Demetri GD, Sicinska E. Preclinical Modeling of Leiomyosarcoma Identifies Susceptibility to Transcriptional CDK Inhibitors through Antagonism of E2F-Driven Oncogenic Gene Expression. Clin Cancer Res. 2022 Jun 1;28(11):2397-2408. doi: 10.1158/1078-0432.CCR-21-3523. PubMed PMID: 35325095; PubMed Central PMCID: PMC9167705.
Hemming ML, Bhola P, Loycano MA, Anderson JA, Taddei ML, Doyle LA, Lavrova E, Andersen JL, Klega KS, Benson MR, Crompton BD, Raut CP, George S, Letai A, Demetri GD, Sicinska E. Preclinical Modeling of Leiomyosarcoma Identifies Susceptibility to Transcriptional CDK Inhibitors through Antagonism of E2F-Driven Oncogenic Gene Expression. Clin Cancer Res. 2022 Jun 1;28(11):2397-2408. doi: 10.1158/1078-0432.CCR-21-3523. PubMed PMID: 35325095; PubMed Central PMCID: PMC9167705.
Kasper B, Achee A, Schuster K, Wilson R, van Oortmerssen G, Gladdy RA, Hemming ML, Huang P, Ingham M, Jones RL, Pollack SM, Reinke D, Sanfilippo R, Schuetze SM, Somaiah N, Van Tine BA, Wilky B, Okuno S, Trent J. Unmet Medical Needs and Future Perspectives for Leiomyosarcoma Patients-A Position Paper from the National LeioMyoSarcoma Foundation (NLMSF) and Sarcoma Patients EuroNet (SPAEN). Cancers (Basel). 2021 Feb 20;13(4). doi: 10.3390/cancers13040886. Review. PubMed PMID: 33672607; PubMed Central PMCID: PMC7924026.
Kasper B, Achee A, Schuster K, Wilson R, van Oortmerssen G, Gladdy RA, Hemming ML, Huang P, Ingham M, Jones RL, Pollack SM, Reinke D, Sanfilippo R, Schuetze SM, Somaiah N, Van Tine BA, Wilky B, Okuno S, Trent J. Unmet Medical Needs and Future Perspectives for Leiomyosarcoma Patients-A Position Paper from the National LeioMyoSarcoma Foundation (NLMSF) and Sarcoma Patients EuroNet (SPAEN). Cancers (Basel). 2021 Feb 20;13(4). doi: 10.3390/cancers13040886. Review. PubMed PMID: 33672607; PubMed Central PMCID: PMC7924026.
Hemming ML, Fan C, Raut CP, Demetri GD, Armstrong SA, Sicinska E, George S. Oncogenic Gene-Expression Programs in Leiomyosarcoma and Characterization of Conventional, Inflammatory, and Uterogenic Subtypes. Mol Cancer Res. 2020 Sep;18(9):1302-1314. doi: 10.1158/1541-7786.MCR-20-0197. Epub 2020 Jun 9. PubMed PMID: 32518213; PubMed Central PMCID: PMC7484251.
Hemming ML, Fan C, Raut CP, Demetri GD, Armstrong SA, Sicinska E, George S. Oncogenic Gene-Expression Programs in Leiomyosarcoma and Characterization of Conventional, Inflammatory, and Uterogenic Subtypes. Mol Cancer Res. 2020 Sep;18(9):1302-1314. doi: 10.1158/1541-7786.MCR-20-0197. Epub 2020 Jun 9. PubMed PMID: 32518213; PubMed Central PMCID: PMC7484251.
Hemming ML, Klega KS, Rhoades J, Ha G, Acker KE, Andersen JL, Thai E, Nag A, Thorner AR, Raut CP, George S, Crompton BD. Detection of Circulating Tumor DNA in Patients With Leiomyosarcoma With Progressive Disease. JCO Precis Oncol. 2019;2019. doi: 10.1200/PO.18.00235. Epub 2019 Jan 24. PubMed PMID: 30793095; PubMed Central PMCID: PMC6380497.
Hemming ML, Klega KS, Rhoades J, Ha G, Acker KE, Andersen JL, Thai E, Nag A, Thorner AR, Raut CP, George S, Crompton BD. Detection of Circulating Tumor DNA in Patients With Leiomyosarcoma With Progressive Disease. JCO Precis Oncol. 2019;2019. doi: 10.1200/PO.18.00235. Epub 2019 Jan 24. PubMed PMID: 30793095; PubMed Central PMCID: PMC6380497.
Translocation-Related Sarcoma Publications:
Hemming ML, Nathenson MJ, Lin JR, Mei S, Du Z, Malik K, Marino-Enriquez A, Jagannathan JP, Sorger PK, Bertagnolli M, Sicinska E, Demetri GD, Santagata S. Response and mechanisms of resistance to larotrectinib and selitrectinib in metastatic undifferentiated sarcoma harboring oncogenic fusion of NTRK1. JCO Precis Oncol. 2020;4:79-90. doi: 10.1200/po.19.00287. Epub 2020 Feb 14. PubMed PMID: 32133433; PubMed Central PMCID: PMC7055910.
Hemming ML, Nathenson MJ, Lin JR, Mei S, Du Z, Malik K, Marino-Enriquez A, Jagannathan JP, Sorger PK, Bertagnolli M, Sicinska E, Demetri GD, Santagata S. Response and mechanisms of resistance to larotrectinib and selitrectinib in metastatic undifferentiated sarcoma harboring oncogenic fusion of NTRK1. JCO Precis Oncol. 2020;4:79-90. doi: 10.1200/po.19.00287. Epub 2020 Feb 14. PubMed PMID: 32133433; PubMed Central PMCID: PMC7055910.
Brien GL, Remillard D, Shi J, Hemming ML, Chabon J, Wynne K, Dillon ET, Cagney G, Van Mierlo G, Baltissen MP, Vermeulen M, Qi J, Fröhling S, Gray NS, Bradner JE, Vakoc CR, Armstrong SA. Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma. Elife. 2018 Nov 15;7. doi: 10.7554/eLife.41305. PubMed PMID: 30431433; PubMed Central PMCID: PMC6277197.
Brien GL, Remillard D, Shi J, Hemming ML, Chabon J, Wynne K, Dillon ET, Cagney G, Van Mierlo G, Baltissen MP, Vermeulen M, Qi J, Fröhling S, Gray NS, Bradner JE, Vakoc CR, Armstrong SA. Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma. Elife. 2018 Nov 15;7. doi: 10.7554/eLife.41305. PubMed PMID: 30431433; PubMed Central PMCID: PMC6277197.
Hemming ML, Wagner AJ, Nucci MR, Chiang S, Wang L, Hensley ML, George S. YWHAE-rearranged high-grade endometrial stromal sarcoma: Two-center case series and response to chemotherapy. Gynecol Oncol. 2017 Jun;145(3):531-535. doi: 10.1016/j.ygyno.2017.03.021. Epub 2017 Apr 5. PubMed PMID: 28390819; PubMed Central PMCID: PMC5471810.
Hemming ML, Wagner AJ, Nucci MR, Chiang S, Wang L, Hensley ML, George S. YWHAE-rearranged high-grade endometrial stromal sarcoma: Two-center case series and response to chemotherapy. Gynecol Oncol. 2017 Jun;145(3):531-535. doi: 10.1016/j.ygyno.2017.03.021. Epub 2017 Apr 5. PubMed PMID: 28390819; PubMed Central PMCID: PMC5471810.
Page updated
Google Sites
Report abuse